Document is current

Article History

Received: 7 November 2022

Accepted: 30 December 2022

First Online: 2 February 2023

Declarations

:

: As the study is led from England, approval from a REC in England was sought, and this study has been reviewed and given a favourable opinion by London - Harrow REC (Ref: 19/LO/0555). The HRA has also given governance approval. In addition, the study was reviewed and given approval by Scotland A REC (REF 21/SS/0002), which is specifically related to the inclusion of patients who lack the capacity to consent in Scotland.Written, informed consent to participate will be obtained from all participants with capacity. Participants have the right to withdraw from the study at any time and for any reason, and all participants are made aware that withdrawal will not affect their routine care. The study will include patients who lack capacity, and as appropriate, consultee declaration will be sought from a personal or nominated consultee (in England, Wales, and Northern Ireland) or consent will be sought from a guardian, welfare attorney, or nearest relative (in Scotland). The process for seeking consultee declaration for patients lacking capacity in England, Wales, and Northern Ireland has been approved by the Research Ethics Committee in England and will be in accordance with the Mental Capacity Act 2005 for England and Wales and in accordance with the Mental Capacity Act (NI) 2016 for Northern Ireland. The process for seeking consent for patients who lack capacity in Scotland will be in accordance with the Adults with Incapacity Act (Scotland) 2000 and approved by the Research Ethics Committee in Scotland. The Mental Capacity Act 2005, the Mental Capacity Act (NI) 2016, and the Adults with Incapacity Act (Scotland) 2000 establish a framework for the protection of the rights of people who lack the capacity to decide for themselves. They are designed to ensure that the interests and rights of people who lack capacity are protected and that their current and previously expressed wishes are respected.

: Not applicable since there are no identifying images or other personal or clinical details of participants presented. Informed consent materials are available from the corresponding author.

: P Bates holds educational contracts with Johnson and Johnson and Zimmer Biomet, for delivering teaching, visitations, and webinars. He is one of the design surgeons for a pelvic plating system, <i>Phoenix</i> manufactured by ITS. Importantly, this plating system is not used in the treatment of fragility LC-1 pelvic fractures. He is a senior lecturer at QMUL, in Orthopaedic Trauma Sciences.C McDaid is a member of the NIHR HTA and EME Journal Editorial Board and has received funding from the British Orthopaedic Association to support grant applications.C Hewitt is a member of the NIHR HTA commissioning committee (2015 to present) and Deputy Chair (2019 to present).These associations and grants have not in any way influenced the contribution to this study.The other authors declare that they have no competing interests.